Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 6, 2004, Pages 1621-1628

  Gebauer, Gerhard ^a   Mueller, Natalia ^a   Fehm, Tanja ^a   Berkholz, Alexander ^a   Beck, Eberhard P ^a   Jaeger, Wolfram ^a   Licht, Peter ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chemotherapy; Doxorubicin; Drug conjugate; Gonadotropin; Ovarian cancer

Indexed keywords

8 BROMO CYCLIC AMP; ADENOSINE KINASE; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN RECEPTOR; DOXORUBICIN; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; LUTEINIZING HORMONE RECEPTOR;

CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG CONJUGATION; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; BASE SEQUENCE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, LH; RNA, MESSENGER; SAMPLING STUDIES; TUMOR CELLS, CULTURED;

EID: 3442875881     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.03.045     Document Type: Conference Paper

References (25)

1. McGuire W.P., Brady M.F., Ozols R.F. The Gynecologic Oncology Group experience in ovarian cancer. Ann Oncol. 10:(suppl):1999;29-34
2. Magrath T. Targeted approaches to cancer therapy. Int J Cancer. 56:1994;163-166
3. Lutsenko S.V., Feldman N.B., Severin S.E. Cytotoxic and antitumor activities of doxorubicin conjugates with the epidermal growth factor and its receptor-binding fragment. J Drug Target. 10:2002;567-571
4. Li H., Qian Z.M. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 22:2002;225-250
5. Dillman R.O. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 19:2001;833-841
6. Licht P., Wildt L. Gonadal and extragonadal receptors for human chorionic gonadotropin (hCG) and luteinizing hormone (LH). Assisted Reproduction Reviews. 8:1998;152-172
7. Lei Z.M., Rao C.V., Ackerman D.M., Day T.G. The expression of human chorionic gonadotropin/human luteinizing hormone receptors in human gestational trophoblastic neoplasms. J Clin Endocrinol Metab. 74:1992;1236-1241
8. Mandai M., Konishi I., Kuroda H., Fukumoto M., Komatsu T., Yamamoto S., et al. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur J Cancer. 33:1997;1501-1507
9. Meduri G., Charnaux N., Loosfelt H., Jolivet A., Spyratos F., Brailly S., et al. Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res. 57:1997;857-864
10. Gebauer G., Fehm T., Beck E., Berkholz A., Licht P., Jager W. Cytotoxic effect of conjugates of doxorubicin and human chorionic-gonadotropin (hCG) in breast cancer cells. Breast Cancer Res Treat. 77:2003;125-131
11. Beck E.P., Vincenti D., Licht P., Berkholz A., Jager W., Lang N., et al. In vitro activity of human chorionic gonadotropin (hCG)-doxorubicin conjugates against ovarian cancer cells. Anticancer Res. 20:2000;3001-3006
12. Hipkin R.W., Sanchez-Yague J., Ascoli M. Agonist-induced phosphorylation of the luteinizing hormone/chorionic gonadotropin receptor expressed in a stably transfected cell line. Mol Endocrinol. 7:1993;823-832
13. Rousseau-Merck M.F., Misrahi M., Atger M., Loosfelt H., Milgrom E., Berger R. Localization of the human luteinizing hormone/choriogonadotropin receptor gene (LHCGR) to chromosome 2p21. Cytogenet Cell Genet. 54:1990;77-79
14. Gudermann T., Birnbaumer M., Birnbaumer L. Evidence for dual coupling of the murine luteinizing hormone receptor to adenylyl cyclase and phosphoinositide breakdown and Ca2+ mobilization: studies with the cloned murine luteinizing hormone receptor expressed in L cells. J Biol Chem. 267:1992;4479-4488
15. Bristow R.E., Karlan B.Y. The risk of ovarian cancer after treatment for infertility. Curr Opin Obstet Gynecol. 8:1996;32-37
16. Page M., Thibeault D., Noel C., Dumas L. Coupling a preactivated daunorubicin derivate to antibody: a new approach. Anticancer Res. 10:1990;353-358
17. Bernhardt G., Reile H., Birnböck H., Spruss T., Schönenberger H. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol. 118:1992;35-43
18. Licht P., Wildt L. Multiplex nested rT-PCR for sensitive and specific detection of full-length hCG/LH receptor messenger RNA. Hum Reprod. 11:1996;12
19. Biskind M.S., Biskind G.S. Development of tumors in the rat ovary after transplantation into spleen. Proc Soc Exp Biol Med. 55:1944;176-179
20. Jager W., Dittrich R., Recabarren S., Wildt L., Lang N. Induction of ovarian tumors by endogenous gonadotropins in rats bearing intrasplenic ovarian grafts. Tumour Biol. 16:1995;268-280
21. Nelson S., Ascoli M. Epidermal growth factor, a phorbol ester, and 3′,5′-cyclic adenosine monophosphate decrease the transcription of the luteinizing hormone/chorionic gonadotropin receptor gene in MA-10 Leydig tumor cells. Endocrinology. 131:1992;615-620
22. Nimrod A. The induction of ovarian LH-receptors by FSH is mediated by cyclic AMP. FEBS Lett. 131:1981;31-33
23. Chuzel F., Clark A.M., Avallet O., Saez J.M. Transcriptional regulation of the lutropin/human choriogonadotropin receptor and three enzymes of steroidogenesis by growth factors in cultured pig Leydig cells. Eur J Biochem. 239:1996;8-16
24. Licht P., von Wolff M., Berkholz A., Wildt L. Evidence for a cycle-dependent expression of full-length human chorionic gonadotropin/ luteinizing hormone receptor mRNA in human endometrium and decidua. Fertil Steril. 79:(suppl):2003;718-723
25. Steinmeyer C., Berkholz A., Gebauer G., Jager W. The expression of hCG receptor mRNA in four human ovarian cancer cell lines varies considerably under different experimental conditions. Tumour Biol. 24:2003;13-22